Organon & (OGN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.85
- Estimate
- $1.07
- Surprise
- -20.6%
- Revenue (period 2026-06-30)
- $1.56B
- Score at report (before → after)
- 5.9 → 5.9/10
Revenue source: xbrl.
How the report landed
Organon & (OGN) missed the $1.07 estimate with diluted EPS of $0.85 — a large 20.6% shortfall. TrendMatrix's engine moved from Sell (5.9/10) to Hold at 5.9/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates OGN Sell at 4.9/10.
1 of the last 4 quarters beat the estimate; this quarter's -20.6% surprise compares with a -10.6% four-quarter average. Next scheduled report: 2026-11-09.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Attractive valuation
What argues against it
- Concentration risk — Geographic: outside United States (74.0%)
- Concentration risk — Product: Established Brands (59.0%)
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $13.78
- Price target
- $15.85
- Stop
- $13.72
- Upside to target
- +15.0%
The stock trades at 17.7× trailing but 3.8× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 79 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
OGN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $3.62B
- P/E (fwd)
- 3.8
- P/E (ttm)
- 17.7
- 52-week range
- $5.69–$13.79
- Off 52-week high
- 0.0%
- RSI (14)
- 79
- Volume vs avg
- 0.31×
- Score today
- 4.9/10